Study lotion for Netherton syndrome safety and symptom improvement
Part of Genetic & congenital, Skin clinical trials.
This trial tests a prescription lotion (QRX003) to see if it is safe and helpful for people with Netherton syndrome. Because the study checks skin symptoms on certain body areas and closely controls other treatments, it may be best for patients who can keep their current regimen stable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 14 years old and able to follow the study pregnancy rules
- You must have a confirmed diagnosis of Netherton syndrome (or agree to genetic testing to confirm it)
- You must have Netherton syndrome skin lesions on the study areas (arms or lower legs)
- Your general health must be good enough for study visits and assessments
- Before starting, you must already be on stable systemic (whole-body) treatment for Netherton syndrome that can stay the same during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a lotion called QRX003 for Netherton syndrome, a rare skin condition. It aims to see if the lotion is safe and helpful for managing symptoms.
This study tests a new lotion (QRX003) designed to treat Netherton Syndrome, a rare genetic skin condition. The lotion is applied to affected skin areas to see if it can reduce symptoms and improve skin health.
This trial tests a new drug called BCX17725 in people with Netherton syndrome to see if it is safe and how the body handles it. It may help by reducing skin symptoms like redness and scaling.
This study looks at the bacteria on the skin and in the gut of people with Netherton syndrome, a condition that affects the skin barrier and often causes allergies. It also compares these findings to healthy volunteers to understand how the microbiome might be different.
This study looks at “skin and blood biomarkers,” meaning measurable signs in the body, in people with ichthyosis to better understand the condition. It may help researchers find ways to track disease activity and evaluate future treatments.
This study tests if a new drug called nemolizumab can help reduce itch in women with lichen sclerosus (LS) in the genital area. Participants must have tried topical steroids before.
Hear when a new Netherton Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.